Institution
Khoo Teck Puat Hospital
Healthcare•Singapore, Singapore•
About: Khoo Teck Puat Hospital is a healthcare organization based out in Singapore, Singapore. It is known for research contribution in the topics: Population & Medicine. The organization has 1356 authors who have published 1490 publications receiving 17149 citations. The organization is also known as: KTPH.
Topics: Population, Medicine, Diabetes mellitus, Type 2 diabetes, Health care
Papers
More filters
••
TL;DR: In this paper, the effects of 6-month-duration interventions with nutritional supplementation, physical training, cognitive training, and combination treatment vs control in reducing frailty among community-dwelling prefrail and frail older persons were compared.
424 citations
••
National University of Singapore1, University of the Philippines2, Singapore General Hospital3, University of Indonesia4, University of Malaya5, Penang Adventist Hospital6, Sarawak General Hospital7, Davao Doctors Hospital8, Makati Medical Center9, Korea University10, Yonsei University11, Seoul National University12, St Mary's Hospital13, University of Ulsan14, Chang Gung University15, China Medical University (Taiwan)16, National Taiwan University17, Auckland City Hospital18, University of Sydney19, Khoo Teck Puat Hospital20
TL;DR: In patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib, and the improved toxicity profile of RE may inform treatment choice in selected patients.
Abstract: Purpose Selective internal radiation therapy or radioembolization (RE) shows efficacy in unresectable hepatocellular carcinoma (HCC) limited to the liver. This study compared the safety and efficacy of RE and sorafenib in patients with locally advanced HCC. Patients and Methods SIRveNIB (selective internal radiation therapy v sorafenib), an open-label, investigator-initiated, phase III trial, compared yttrium-90 (90Y) resin microspheres RE with sorafenib 800 mg/d in patients with locally advanced HCC in a two-tailed study designed for superiority/detriment. Patients were randomly assigned 1:1 and stratified by center and presence of portal vein thrombosis. Primary end point was overall survival (OS). Efficacy analyses were performed in the intention-to-treat population and safety analyses in the treated population. Results A total of 360 patients were randomly assigned (RE, 182; sorafenib, 178) from 11 countries in the Asia-Pacific region. In the RE and sorafenib groups, 28.6% and 9.0%, respectively, failed to receive assigned therapy without significant cross-over to either group. Median OS was 8.8 and 10.0 months with RE and sorafenib, respectively (hazard ratio, 1.1; 95% CI, 0.9 to 1.4; P = .36). A total of 1,468 treatment-emergent adverse events (AEs) were reported (RE, 437; sorafenib, 1,031). Significantly fewer patients in the RE than sorafenib group had grade ≥ 3 AEs (36 of 130 [27.7%]) v 82 of 162 [50.6%]; P < .001). The most common grade ≥ 3 AEs were ascites (five of 130 [3.8%] v four of 162 [2.5%] patients), abdominal pain (three [2.3%] v two [1.2%] patients), anemia (zero v four [2.5%] patients), and radiation hepatitis (two [1.5%] v zero [0%] patients). Fewer patients in the RE group (27 of 130 [20.8%]) than in the sorafenib group (57 of 162 [35.2%]) had serious AEs. Conclusion In patients with locally advanced HCC, OS did not differ significantly between RE and sorafenib. The improved toxicity profile of RE may inform treatment choice in selected patients.
422 citations
••
TL;DR: A meta-analysis of genome-wide association studies for estimated glomerular filtration rate suggests that genetic determinants of eGFR are mediated largely through direct effects within the kidney and highlight important cell types and biological pathways.
Abstract: Reduced glomerular filtration rate defines chronic kidney disease and is associated with cardiovascular and all-cause mortality. We conducted a meta-analysis of genome-wide association studies for estimated glomerular filtration rate (eGFR), combining data across 133,413 individuals with replication in up to 42,166 individuals. We identify 24 new and confirm 29 previously identified loci. Of these 53 loci, 19 associate with eGFR among individuals with diabetes. Using bioinformatics, we show that identified genes at eGFR loci are enriched for expression in kidney tissues and in pathways relevant for kidney development and transmembrane transporter activity, kidney structure, and regulation of glucose metabolism. Chromatin state mapping and DNase I hypersensitivity analyses across adult tissues demonstrate preferential mapping of associated variants to regulatory regions in kidney but not extra-renal tissues. These findings suggest that genetic determinants of eGFR are mediated largely through direct effects within the kidney and highlight important cell types and biological pathways.
409 citations
••
TL;DR: It is demonstrated that peripheral blood microRNAs can be developed as unique biomarkers that are reflective and predictive of metabolic health and disorder.
Abstract: Background
Dysregulation of microRNA (miRNA) expression in various tissues and body fluids has been demonstrated to be associated with several diseases, including Type 2 Diabetes mellitus (T2D). Here, we compare miRNA expression profiles in different tissues (pancreas, liver, adipose and skeletal muscle) as well as in blood samples from T2D rat model and highlight the potential of circulating miRNAs as biomarkers of T2D. In parallel, we have examined the expression profiles of miRNAs in blood samples from Impaired Fasting Glucose (IFG) and T2D male patients.
402 citations
••
TL;DR: Plasma irisin levels appear to be associated with important metabolic factors in non-diabetic subjects but not in individuals with type 2 diabetes.
Abstract: Aims Irisin is a novel myokine secreted in response to PPAR-γ co-activator-1α (PGC-1α) activation. Earlier studies suggested that PGC-1α expression and activity were lower in myocytes in type 2 diabetes mellitus (T2DM). Therefore, we hypothesize that circulating irisin levels are lower in T2DM patients. Methods In this observational study, we recruited 96 T2DM subjects and 60 non-diabetic control subjects. Among T2DM subjects, 38% were on insulin treatment, 78% were taking statins and 72% were taking renin-angiotensin system antagonists. Circulating irisin was quantified by ELISA and its association with markers of metabolic phenotype was analyzed by Pearson bivariate correlation and multiple linear regression. Results Circulating irisin was significantly lower in individuals with T2DM compared with non-diabetic controls (T2DM 204 ± 72 ng/ml vs. non-diabetic control 257 ± 24 ng/ml, p Conclusions Circulating irisin is lower in T2DM compared with non-diabetic controls. Plasma irisin levels appear to be associated with important metabolic factors in non-diabetic subjects but not in individuals with type 2 diabetes.
389 citations
Authors
Showing all 1371 results
Name | H-index | Papers | Citations |
---|---|---|---|
Jianjun Liu | 112 | 1040 | 71032 |
Olle Melander | 109 | 783 | 75911 |
Kent D. Taylor | 104 | 550 | 53004 |
Raymond T. Chung | 98 | 729 | 37207 |
Wilfred C. G. Peh | 41 | 348 | 5524 |
Su Chi Lim | 38 | 190 | 7054 |
Xiao Zhang | 31 | 125 | 4535 |
Yingfeng Zheng | 29 | 71 | 13643 |
Michael Wong | 27 | 52 | 6992 |
Jeffrey J. Leow | 27 | 122 | 3155 |
Keng Bee Yap | 26 | 54 | 2382 |
Farnad Imani | 25 | 127 | 1775 |
Vishal G Shelat | 24 | 114 | 2215 |
Chandra M. Kumar | 24 | 112 | 1506 |
Chee Fang Sum | 22 | 106 | 2483 |